Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,680
Views
46
CrossRef citations to date
0
Altmetric
Back Matter

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

Tuba N. Gidea Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia
,
Ines P. Silvaa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia
,
Camelia Queka Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia
,
Tasnia Ahmeda Melanoma Institute Australia, The University of Sydney, Sydney, Australia
,
Alexander M. Menziesa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia;e Royal North Shore Hospital, Sydney, Australia;f Mater Hospital, North Sydney, Australia
,
Matteo S. Carlinoa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia;g Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia
,
Robyn P.M. Sawa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia;d Royal Prince Alfred Hospital, Sydney, Australia;f Mater Hospital, North Sydney, Australia
,
John F. Thompsona Melanoma Institute Australia, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia;d Royal Prince Alfred Hospital, Sydney, Australia;f Mater Hospital, North Sydney, Australia
,
Marcel Battena Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia
,
Georgina V. Longa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia;e Royal North Shore Hospital, Sydney, Australia;f Mater Hospital, North Sydney, AustraliaORCID Iconhttps://orcid.org/0000-0001-8894-3545
ORCID Icon,
Richard A. Scolyera Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, Australia;d Royal Prince Alfred Hospital, Sydney, Australia
&
James S. Wilmotta Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Sydney Medical School, The University of Sydney, Sydney, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6750-5244
ORCID Icon show all
Article: 1659093 | Received 27 Mar 2019, Accepted 18 Aug 2019, Published online: 16 Oct 2019

References

  • Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New Engl J Med. 2017;377:1345–11. doi:10.1056/NEJMoa1709684.
  • Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. 2017;23:5024–5033. doi:10.1158/1078-0432.CCR-16-0698.
  • Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;100:88–98. doi:10.1016/j.critrevonc.2016.02.001.
  • Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018;101:236–243. doi:10.1016/j.ejca.2018.06.034.
  • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571. doi:10.1038/nature13954.
  • Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63:675–683. doi:10.1007/s00262-014-1545-8.
  • Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigm. Cell Melanoma Res. 2015;28:245–253. doi:10.1111/pcmr.12340.
  • Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, Mcneil C, Kalinka-Warzocha E, et al. Nivolumab in Previously untreated melanoma without BRAF mutation. New Engl J Med. 2015;372:320–330. doi:10.1056/NEJMoa1412082.
  • Carlino M, Ribas A, Gonzalez R, Hoeller C, Bar-Sela G, Barrow C, Chao D, Wolter P, Berking C, Straume O, Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma. Cancer Res. 2016;76:CT004–CT004.
  • Berthel A, Zoernig I, Valous NA, Kahlert C, Klupp F, Ulrich A, Weitz J, Jaeger D, Halama N. Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival. Oncol Immunol. 2017;6:e1286436. doi:10.1080/2162402X.2017.1286436.
  • Barua S, Fang P, Sharma A, Fujimoto J, Wistuba I, Rao AUK, Lin SH. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer. 2018;117:73–79. doi:10.1016/j.lungcan.2018.01.022.
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026.
  • Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35:238–255.e6. doi:10.1016/j.ccell.2019.01.003.
  • Johnson KS (2018). phenoptr: inForm helper functions. R package version 0.1.3.
  • Carstens JL, Correa De Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, Lebleu VS, Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095. doi:10.1038/ncomms15095.
  • Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862. doi:10.1371/journal.pone.0051862.
  • Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, Mcarthur GA, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017;67:472–492. doi:10.3322/caac.21409.
  • Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res. 2016;18:78. doi:10.1186/s13058-016-0737-x.
  • Giraldo NA, Nguyen P, Engle EL, Kaunitz GJ, Cottrell TR, Berry S, Green B, Soni A, Cuda JD, Stein JE, et al. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer. 2018;6:99. doi:10.1186/s40425-018-0404-0.
  • Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, et al. Quantitative spatial profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin Cancer Res. 2018;24:5250–5260. doi:10.1158/1078-0432.CCR-18-0309.
  • Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–313. doi:10.1038/nature10762.
  • Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
  • Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, et al. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. Sci Rep. 2018;8:11158. doi:10.1038/s41598-018-28944-3.
  • Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.
  • Donizy P, Biecek P, Kaczorowski M, Halon A, Maciejczyk A, Matkowski R. Contrary effect of two types of spatial distribution (diffuse versus marginal) of CD8-positive lymphocytes on clinical outcome in melanoma patients. Int J Clin Exp Pathol. 2016;9:8415–8423.
  • Wagner NB, Forschner A, Leiter U, Garbe C, Eigentler TK. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer. 2018;119:339–346. doi:10.1038/s41416-018-0167-x.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa1504030.
  • Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33:890–904.e5. doi:10.1016/j.ccell.2018.03.017.
  • Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, Li X, Miao X, Li S, Mi X, et al. Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis. Cell. 2019;176:1113–1127.e16. doi:10.1016/j.cell.2019.01.002.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.